Elizabeth H. Kerling

Elizabeth H. Kerling

Auto-generated profile, based on publicly available information

Elizabeth H. Kerling

Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, KS, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
SCSusan Elaine Carlson
Susan Elaine Carlson
JCJohn Colombo
John Colombo
BGByron J Gajewski
Byron J Gajewski
KGKathleen M. Gustafson
Kathleen M. Gustafson
DMDavid Mundy
David Mundy
DSD Jill Shaddy
D Jill Shaddy
Background: Observational studies associate higher intakes of n−3 (omega-3) long-chain polyunsaturated fatty acids (LCPUFAs) during pregnancy with hig

1 August 2013 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
JCJohn Colombo
John Colombo
SCSusan Elaine Carlson
Susan Elaine Carlson
CCCarol Cheatham
Carol Cheatham
DSD Jill Shaddy
D Jill Shaddy
EKElizabeth H Kerling
Elizabeth H Kerling
CBCaitlin Brez
Caitlin Brez
Background: The effect of long-chain polyunsaturated fatty acid (LCPUFA) intake on cognitive development is controversial. Most randomized trials hav

1 July 2016 in Journal of Nutrition Education and Behavior
Verified
Journal Article
Closed access
HGHeather Gibbs
Heather Gibbs
AKAmy R. Kennett
Amy R. Kennett
EKElizabeth H. Kerling
Elizabeth H. Kerling
QYQing Yu
Qing Yu
BGByron Gajewski
Byron Gajewski
DSDebra Kay Sullivan
Debra Kay Sullivan

1 June 2017 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Open access
JCJohn Colombo
John Colombo
DSD. Jill Shaddy
D. Jill Shaddy
EKElizabeth H. Kerling
Elizabeth H. Kerling
KGKathleen M. Gustafson
Kathleen M. Gustafson
SCSusan Elaine Carlson
Susan Elaine Carlson
The DHA Intake and Measurement of Neural Development (DIAMOND) trial represents one of only a few studies of the long-term dose-response effects of LCPUFA-supplemented formula feeding during infancy. The trial contrasted the effects of four formulations: 0.00% docosahexaenoic acid (DHA)/0.00% arachidonic acid (ARA), 0.32% DHA/0.64% ARA, 0.64% DHA/0.64% ARA, and 0.96% DHA/0.64% ARA against a control condition (0.00% DHA/0.00% ARA). The results of this trial have been published elsewhere, and show improved cognitive outcomes for infants fed supplemented formulas, but a common finding among many of the outcomes show a reduction of benefit for the highest DHA dose (i.e., 0.96%DHA/0.64% ARA, that is, a DHA: ARA ratio 1.5:1.0). The current paper gathers and summarizes the evidence for the reduction of benefit at this dose, and in an attempt to account for this reduced benefit, presents for the first time data from infants' red blood cell (RBC) assays taken at 4 and 12 months of age. Those assays indicate that blood DHA levels generally rose with increased DHA supplementation, although those levels tended to plateau as the DHA-supplemented level exceeded 0.64%. Perhaps more importantly, ARA levels showed a strong inverted-U function in response to increased DHA supplementation; indeed, infants assigned to the formula with the highest dose of DHA (and highest DHA/ARA ratio) showed a reduction in blood ARA relative to more intermediate DHA doses. This finding raises the possibility that reduced ARA may be responsible for the reduction in benefit on cognitive outcomes seen at this dose. The findings implicate the DHA/ARA balance as an important variable in the contribution of LCPUFAs to cognitive and behavioral development in infancy.

27 November 2015 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
AFAmanda M. Foiles
Amanda M. Foiles
EKElizabeth H. Kerling
Elizabeth H. Kerling
JWJo A. Wick
Jo A. Wick
DSDeolinda M. F. Scalabrin
Deolinda M. F. Scalabrin
JCJohn Colombo
John Colombo
SCSusan Elaine Carlson
Susan Elaine Carlson

20 April 2019 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
JCJohn Colombo
John Colombo
DSD Jill Shaddy
D Jill Shaddy
KGKathleen M. Gustafson
Kathleen M. Gustafson
BGByron J Gajewski
Byron J Gajewski
JTJocelynn M Thodosoff
Jocelynn M Thodosoff
SCSusan E Carlson
Susan E Carlson
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid that has been linked to improved vision and cognition in postnatal feeding studies and has been consistently associated with reduction of early preterm birth in prenatal supplementation trials. This is a report of the first long-term follow-up of infants from mothers receiving prenatal DHA supplementation in a US cohort. Our objective was to evaluate the efficacy of the prenatal supplementation on both global and granular longitudinal assessments of cognitive and behavioral development. In a randomized double-blind clinical trial, mothers received either 600 mg/d of DHA or a placebo beginning at 14.5 weeks of gestation and capsules were provided until delivery. Children from those pregnancies were followed by cognitive and behavioral assessments administered from 10 mo through 6 y of age. From 301 mothers in the initial study, ∼200 infants completed the longitudinal schedule. Although this intervention had been shown to reduce high-risk pregnancies and improve visual attention in infants during the first year, only a few positive long-term effects of prenatal DHA supplementation emerged from analyses of this follow-up. Increases in maternal blood DHA during pregnancy were related to verbal and full scale intelligence quotient (IQ) scores at 5 and 6 y, but these effects disappeared after controlling for SES. Maternal blood DHA concentrations at delivery were unrelated to outcomes, although maternal DHA at enrollment was related to productive vocabulary at 18 mo. Although prenatal DHA supplementation substantially reduced early preterm birth and improved visual attention in infancy in this sample, no consistent long-term benefits were observed into childhood. Increases in maternal blood DHA concentration in pregnancy were related to higher IQs but this effect was confounded with SES and disappeared when SES was statistically controlled. This trial was registered at http://www.clinicaltrials.gov as NCT00266825 and NCT02487771.